+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
P

Actively Recruiting

Researchers are evaluating efimosfermin alfa in adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis MASH and stage F2 or F3 liver fibrosis. The study aims to assess the safety and effectiveness of efimosfermin alfa compared to a placebo in resolving steatohepatitis and improving liver-related clinical outcomes. This Phase 3 trial is randomized, double-blind, and placebo-controlled, focusing on participants with specific liver conditions and metabolic syndrome components. Participants are assigned to one of three groups two groups receive different dose levels of efimosfermin alfa, while the third group receives a placebo. Treatments are given under controlled conditions, and the study follows a parallel design. The trial monitors participants at set intervals over a course of 52 weeks, with some outcomes tracked up to 48 months to evaluate long-term effects on liver fibrosis and steatohepatitis. During the study, participants undergo liver biopsies to confirm diagnosis and assess changes. Researchers evaluate improvements in fibrosis stage, steatohepatitis resolution, and various liver function measurements using imaging and blood tests. Safety is monitored by tracking adverse events and laboratory abnormalities. Quality of life and other health indicators are also assessed throughout the study, which lasts several years to capture both short- and long-term outcomes.

Age: 18Years - 75YearsAll GendersPhase 3
91 locations
P

Actively Recruiting

Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.

Age: 18Years - 80YearsAll GendersPhase 3
345 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations
E

Actively Recruiting

Researchers are evaluating the safety, tolerability, and effectiveness of a single injection of PTP-001 MOTYS in treating knee osteoarthritis OA in adults aged 40 to 80 years. This Phase 3, multicenter, randomized, double-blind, placebo-controlled trial compares PTP-001 to a placebo over a 52-week period in participants with mild to moderate knee OA confirmed by X-ray and symptoms. The goal is to assess improvements in knee function and pain over time. Participants will be randomly assigned to receive either a single 200 mg injection of PTP-001 or a placebo injection directly into the affected knee on Day 1. The study includes a screening period of up to 28 days before treatment, followed by the injection day and a 12-month follow-up phase to monitor outcomes. At least 260 participants will take part, split evenly between the two groups. Throughout the study, participants will attend scheduled visits for assessments including knee pain and function questionnaires, such as the WOMAC and PGA-OA scores, at 6, 9, and 12 months. Researchers will track improvements in knee symptoms and overall osteoarthritis status, as well as monitor safety and tolerability. Participants are expected to comply with study visits and restrictions, using only acetaminophen as needed for pain relief during the trial.

Age: 40Years - 80YearsAll GendersPhase 3
18 locations
E

Actively Recruiting

Researchers are evaluating a new way to deliver treatment using the ECAP-controlled closed-loop spinal cord stimulation SCS system called the Evoke System. This study focuses on patients who experience chronic pain in the trunk andor limbs. The goal is to test and assess new software and hardware features that may improve how the Evoke System delivers treatment. Participants will use the Evoke Spinal Cord Stimulation System, which measures electrical activity called evoked compound action potentials ECAPs. The device automatically adjusts the stimulation current to keep the ECAP amplitude consistent. This study involves a single group of participants using this novel device and will continue through to study completion, which may last up to two years. During the study, participants will be monitored for changes in ECAPs measured by the Evoke System. Researchers will evaluate these changes over the course of the study to understand how the device functions with the new features. Participants will need to provide informed consent and comply with study requirements while using the device. The total participation time can last up to two years, with regular assessments conducted throughout this period.

Age: 18Years +All GendersPhase Not Applicable
25 locations
R

Actively Recruiting

This research aims to review anonymous medical records to study the clinical outcomes of various treatments for chronic pain. It is a retrospective, multi-center data review that includes multiple patient groups to evaluate different treatment approaches. The study focuses on patients who have been implanted with or are eligible for spinal cord stimulation systems or other treatments such as radiofrequency RF or intrathecal drug delivery systems IDS. The study compares different treatment methods, including Boston Scientific devices and non-Boston Scientific systems like spinal cord stimulation, RF, and IDS. It involves two groups patients eligible for these treatments and those who have received a prior treatment followed by a different chronic pain therapy. This evaluation uses de-identified data collected from medical charts without direct patient intervention. Participants involvement consists of reviewing their past medical data over approximately two years. Researchers will measure the responder rate, which indicates the effectiveness of the treatments through the study period. Since this is a data review, there are no active treatments or visits required, and patient privacy is maintained throughout the study.

Age: 18Years +All Genders
145 locations
G

Actively Recruiting

This research aims to gather real-world data on the outcomes of Boston Scientific neurostimulation systems used for pain management in everyday clinical practice. It focuses on evaluating the long-term effectiveness, economic value, and technical performance of these commercially approved neurostimulation devices when used according to their instructions. Participants will undergo a trial period with a Boston Scientific neurostimulation system for pain. Those who experience positive results from the trial may then receive a permanent implant of the neurostimulation system. The therapy will be personalized based on the investigators judgment and routine site care, following the studys inclusion and exclusion criteria. During the study, participants will be monitored as they receive neurostimulation therapy in real-world settings. Researchers will collect information on treatment outcomes and device performance over time. The study spans from 2012 to 2035, allowing for long-term observation of participants using these neurostimulation systems for pain relief.

Age: 18Years +All Genders
118 locations
R

Actively Recruiting

Researchers are studying adults aged 18 to 70 with chronic painful lumbosacral radiculopathy, also known as sciatica, to evaluate the safety and tolerability of a drug called C-1101. This phase 1 clinical trial compares a single dose of C-1101 given as a transforaminal epidural injection to a placebo using sterile saline. The study focuses on understanding the side effects and risks of this treatment method. Participants receive one of three escalating doses of C-1101 or a placebo injection administered near the spine. The treatment is given only once during the study. Different dose groups are randomized, and neither the participants nor the researchers know who receives the drug or placebo, ensuring double-blind conditions. During the trial, participants are monitored for adverse events and side effects from the day of treatment until 24 weeks afterward. Researchers assess the severity and frequency of these events to understand treatment safety. Participants will have scheduled visits and evaluations to track their health and response to the injection throughout the study period.

Age: 18Years - 70YearsAll GendersPhase 1
6 locations
S

Actively Recruiting

Researchers are evaluating the safety and performance of the PRIMUS System, a device designed to provide neurostimulation to branches of the trigeminal and occipital nerves, for treating resistant migraine. The study focuses on patients with chronic or high-frequency episodic migraine who have not responded to multiple preventive drug therapies. It aims to assess clinical benefits and safety over a 12-week period. Participants will be randomly assigned in a double-blind manner to one of several groups including active therapy modalities or sham therapy. The PRIMUS System delivers subcutaneous neurostimulation, and the study compares different therapy approaches to evaluate their effects on migraine symptoms. The study is set to run from June 2024 to January 2029. During the study, participants will be monitored over 12 weeks to evaluate both safety and effectiveness. Researchers will assess clinical outcomes related to migraine treatment, with follow-ups as per study protocols. This period will involve treatment administration and regular evaluations to collect data on responses and any side effects experienced.

Age: 18Years - 84YearsAll GendersPhase Not Applicable
11 locations